Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy

Journal: Nature Communications

Published: 2020-01-31

DOI: 10.1038/s41467-020-14471-1

Affiliations: 9

Authors: 31

Go to article
Institutions Share
Department of Melanoma Medical Oncology, MD Anderson Cancer Center, United States of America (USA) 0.59
Nektar Therapeutics, United States of America (USA) 0.17
Department of Molecular and Cellular Biology, BCM, United States of America (USA) 0.08
Department of Infectious Diseases, Infection Control and Employee Health, MD Anderson Cancer Center, United States of America (USA) 0.06
Yale Cancer Center, United States of America (USA) 0.06
Dan L. Duncan Comprehensive Cancer Center, United States of America (USA) 0.02
University of Texas Graduate School of Biomedical Sciences (GSBS), United States of America (USA) 0.01
Department of Immunology, MD Anderson Cancer Center, United States of America (USA) 0.01

Return

Except where otherwise noted © 2021 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER